

Under the High Patronage of His Excellency
the Minister of Public Health
Dr. Jamil Jabak



Lebanese Society of Medical Oncology
الجمعية اللبنانية لأطباء الأورم الخبيث

OFFICIALLY LICENSED
BEST OF ASCO[®]
2019 ANNUAL MEETING



July 12 - 13, 2019 | Hilton Beirut Habtoor Grand - Lebanon



Organized by **The Lebanese Society of Medical Oncology**
Licensed by **The American Society of Clinical Oncology**

www.lsmo-lb.org

Friday July 12, 2019

08:00

REGISTRATION

09:00 - 10:00 Lung Cancer | Non-Small Cell Local-Regional / Small Cell / Thoracic Cancers

Speakers: TBA

Chairs: TBA

- **Abstract 8503:** Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).
(David J. Kwiatkowski, MD, PhD) *Presented by Arafat Tufaily MD*
- **Abstract 8504:** Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.
(Tina Cascone, MD, PhD) *Presented by Arafat Tufaily MD*
- **Abstract 8506:** Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.
(Luis G. Paz-Ares, MD, PhD) *Presented by Fadi Karak MD*

Lung Cancer | Non-Small Cell Metastatic

Speakers: TBA

Chairs: TBA

- **Abstract 9000: RELAY:** A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).
(Kazuhiko Nakagawa, MD, PhD) *Presented by Fadlo Khuri MD*
- **Abstract 9001:** Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).
(Vanita Noronha) *Presented by Fadlo Khuri MD*
- **Abstract 9002:** ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
(Suresh S. Ramalingam, MD) *Presented by Fadlo Khuri MD*

Friday July 12, 2019

10:00 - 10:30 Head and Neck Cancer

Speakers: TBA

Chairs: TBA

▪ **Abstract 6000:** Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

(Danny Rischin) *Presented by Marcel Massoud MD*

▪ **Abstract 6002:** TPEXtreme randomized trial: TPEX versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

(Joel Guigay, MD) *Presented by Fadi Karak MD*

▪ **Abstract 6003:** Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.

(Jun Ma) *Presented by Ziad Salem MD*

10:30 - 11:00 Coffee Break

11:00 - 11:30 Sarcoma

Speakers: TBA

Chairs: TBA

▪ **Abstract LBA3:** ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

(William D. Tap, MD) *Presented by Hazem Assi MD*

▪ **Abstract 11001:** STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.

(Sylvie Bonvalot, MD, PhD) *Presented by Caroline Semaha MD*

▪ **Abstract 11015:** Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARCO28 expansion cohorts.

(Melissa Amber Burgess, MD) *Presented by Rabih Said MD*

Friday July 12, 2019

11:30 - 11:50 Central Nervous System Tumors

Speakers: TBA

Chairs: TBA

▪ **Abstract 2000:** Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion.

(Martin J. Van Den Bent, MD, PhD) *Presented by Hampig Kourie MD*

▪ **Abstract 2001:** Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

(Carmen Balana, MD, PhD) *Presented by Francois Kamar*

12:00 - 12:45 Opening Ceremony

13:00 - 14:00 Lunch Break

Friday July 12, 2019

14:00 - 15:00 Hematologic Malignancies, Part I Leukemia, Myelodysplastic Syndromes, and Allotransplant

Speakers: TBA

Chairs: TBA

▪ **Abstract 7000:** Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

(Mark J. Levis, MD, PhD) *Presented by Ahmad Ibrahim MD*

▪ **Abstract 7005:** ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).

(Timothy P. Hughes) *Presented by Joseph Makdessi MD*

Hematologic Malignancies, Part I Lymphoma and Chronic Lymphocytic Lymphoma

Speakers: TBA

Chairs: TBA

▪ **Abstract 7502:** Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD-) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.

(Kirsten Fischer, MD) *Presented by Fadi Nasr MD*

▪ **Abstract 7506:** Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

(Nathan Hale Fowler) *Presented by Khaled Ibrahim MD*

▪ **Abstract 7510:** Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.

(Paul M. Barr, MD) *Presented by Fadi Nasr MD*

Friday July 12, 2019

15:00 - 15:40 Hematologic Malignancies, Part II | Plasma Cell Dyscrasia

Speakers: TBA

Chairs: TBA

- **Abstract 8001:** E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.
(Sagar Lonial, MD) *Presented by Ahmad Ibrahim MD*
- **Abstract 8004:** A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
(Paul G. Richardson, MD) *Presented by Khaled Ibrahim MD*
- **Abstract 8005:** Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
(Maria-Victoria Mateos, PhD) *Presented by Nabil Chamseddine MD*
- **Abstract 7507:** Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.
(Pieternella J. Lugtenburg) *Presented by Joseph Makdessi MD*

15:40 - 16:00 Coffee Break

16:00 - 16:20 Symptoms and Survivorship

Speakers: TBA

Chairs: TBA

- **Abstract 11503:** A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.
(Hironobu Hashimoto, BPharm) *Presented by Georges Chahine MD*
- **Abstract 11506:** Safety of pregnancy following breast cancer (BC) in patients (pts) carrying a BRCA mutation (mBRCA): Results of an international cohort study.
(Matteo Lambertini, MD) *Presented by Ahmad Awada MD*

Friday July 12, 2019

16:20 - 17:10 Melanoma/Skin Cancers

Speakers: TBA

Chairs: TBA

▪ **Abstract 2512:** Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.

(Alexander M. M. Eggermont, MD) *Presented by Marwan Ghosn MD*

▪ **Abstract 9500:** Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).

(Gerald Fogarty, MD) *Presented by Georges Farha MD*

▪ **Abstract 9501:** Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

(Hussein Abdul-Hassan Tawbi, MD, PhD) *Presented by Marwan Ghosn MD*

▪ **Abstract 9503:** Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

(Alexander M. Menzies, MBBS, FRACP, PhD) *Presented by Wassim Mouchayleh MD*

▪ **Abstract 9507:** Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

(Paul D. Nathan, MD) *Presented by Georges Chahine MD*

Saturday July 13, 2019

09:00 - 09:30 Genitourinary Cancers, PART I | Genitourinary (Prostate) Cancer

Speakers: TBA

Chairs: TBA

▪ **Abstract LBA2:** Overall survival (OS) results of a phase III randomized trial of standard of care therapy with or without enzalutamide for metastatic hormone sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international co-operative group trial.
(Christopher Sweeney) *Presented by Joseph Makdessi MD*

▪ **Abstract 5006:** First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
(Kim N. Chi, MD, FRCPC) *Presented by Nizar Bitar MD*

▪ **Abstract 5008:** Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
(Michael J. Morris, MD) *Presented by Deborah Mukherji MD*

09:30 - 10:10 Genitourinary Cancers, PART II | Genitourinary (NonProstate) Cancer

Speakers: TBA

Chairs: TBA

▪ **Abstract 4500:** Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
(Brian I. Rini, MD, FACP) *Presented by Deborah Mukherji MD*

▪ **Abstract 4503:** CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.
(Jonathan E. Rosenberg, MD) *Presented by Roger Khater MD*

▪ **Abstract 4504:** Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
(Matt D. Galsky, MD, FASCO) *Presented by Joseph Kattan MD*

▪ **Abstract 4505: EV-201:** Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
(Daniel Peter Petrylak, MD) *Presented by Joseph Kattan MD*

Saturday July 13, 2019

10:10 - 11:25 Breast Cancer | Local / Regional / Adjuvant

Speakers: TBA

Chairs: TBA

▪ **Abstract 503:** Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. (Joseph A. Sparano, MD) *Presented by Ahmad Awada MD*

▪ **Abstract 504:** Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM). (Lucia Del Mastro, MD) *Presented by Ghazi Nsouli MD*

▪ **Abstract 508:** Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. (Patricia A. Ganz, MD, FASCO) *Presented by Fares Azouri MD*

Breast Cancer | Metastatic

Speakers: TBA

Chairs: TBA

▪ **Abstract 1000:** SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). (Hope S. Rugo, MD, FASCO) *Presented by Nagi El Saghier MD*

▪ **Abstract 1002:** Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. (Cristina Saura, MD, PhD) *Presented by Ahmad Awada MD*

▪ **Abstract 1003:** IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). (Peter Schmid, MD, PhD, FCRP) *Presented by Walid Moukaddem MD*

▪ **Abstract LBA1008:** Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy \pm ribociclib: Overall survival (OS) results. (Sara A. Hurvitz, MD) *Presented by Hazem Assi MD*

11:25 - 11:45 Coffee Break

Saturday July 13, 2019

11:45 - 12:55 Gastrointestinal Cancers | Gastrointestinal (Colorectal) Cancer

Speakers: Ghassan Abou Alfa, MD - Eileen O'Reilly, MD

Chairs: TBA

▪ **Abstract 3501:** Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

(Timothy Iveson, MD, FRCP) *Presented by Sally Tamraz MD*

▪ **Abstract 3504:** FOXROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

(Matthew T. Seymour, MD) *Presented by Ghassan Abou Alfa MD*

▪ **Abstract 3508:** Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

(Chiara Cremolini, MD) *Presented by Eileen O'Reilly MD*

Gastrointestinal Cancers | Gastrointestinal (Noncolorectal) Cancer

Speakers: TBA

Chairs: TBA

▪ **Abstract LBA4:** Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

(Hedy L. Kindler) *Presented by Eileen O'Reilly MD*

▪ **Abstract 4000:** APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

(Margaret A. Tempero, MD, FASCO) *Presented by Eileen O'Reilly MD*

▪ **Abstract 4003:** ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

(Angela Lamarca, MD, PhD) *Presented by Ghassan Abou Alfa MD*

▪ **Abstract LBA4007:** Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

(Josep Tabernero, MD, PhD) *Presented by Ghassan Abou Alfa MD*

Saturday July 13, 2019

13:00 - 14:00 Lunch Break

14:00 - 15:00 Gynecologic Cancer

Speakers: Muhieddine Seoud, MD & David Atallah, MD

Chairs: TBA

▪ **Abstract 5500:** A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naïve patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial.

(Matthew A. Powell, MD) *Presented by*

▪ **Abstract 5505:** Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.

(Mansoor Raza Mirza, MD) *Presented by*

▪ **Abstract 5506:** Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.

(Richard T. Penson, MD, MRCP) *Presented by*

▪ **Abstract 5508: EWOC-1:** A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

(Claire Falandry) *Presented by*

15:00

Adjourn

Organized by:



LEBANON

4th Floor, Qubic Center
Daoud Ammoun Street
Horsh Tabet - Sin El Fil
P.O. Box: 90-361 Beirut
Tel: +961 1 510880/1/2/3
Mobile: +961 71 103123

UAE

DMCC Business Centre
Almas Tower
Jumeirah Lakes
Dubai, United Arab Emirates
Unit No: 3820
Mobile: +971 50 9110475



infomed@infomedweb.com | www.infomedweb.com